PubMed 36325075

PubMed ID: 36325075

View on PubMed
Polyvalent guide RNAs for CRISPR antivirals.
Authors: Bagchi Rammyani, Tinker-Kulberg Rachel, Salehin Mohammad, Supakar Tinku, Chamberlain Sydney, Ligaba-Osena Ayalew, Josephs Eric A
Journal: iScience (iScience), Vol.25(11), 2022‑Nov‑18

DOI: 10.1016/j.jgg.2020.02.006 PMCID: PMC3967031

Abstract
CRISPR effector Cas13 recognizes and degrades RNA molecules that are complementary to its guide RNA (gRNA) and possesses potential as an antiviral biotechnology because it can degrade viral mRNA and RNA genomes. Because multiplexed targeting is a critical strategy to improve viral suppression, we developed a strategy to design of gRNAs where individual gRNAs have maximized activity at multiple viral targets, simultaneously, by exploiting the molecular biophysics of promiscuous target recognition by Cas13. These "polyvalent" gRNA sequences ("pgRNAs") provide superior antiviral elimination across tissue/organ scales in a higher organism (Nicotiana benthamiana) compared to conventionally-designed gRNAs-reducing detectable viral RNA by >30-fold, despite lacking perfect complementarity with either of their targets and, when multiplexed, reducing viral RNA by >99.5%. Pairs of pgRNA-targetable sequences are abundant in the genomes of RNA viruses, and this work highlights the need for specific approaches to the challenges of targeting viruses in eukaryotes using CRISPR.
Publication Types
Journal Article
Keywords
Biocomputational method Biological sciences tools Computational bioinformatics
Grant Support
Related Articles